Inactive Instrument

News AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

End-of-day quote Nasdaq Other stock markets
- ^USD	-

29/05	Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	MT
17/05	Aeterna Zentaris Finalizes Some Details for Ceapro Merger	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date	30/05	AQ
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	29/05	MT
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	17/05	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	17/05	MT
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro	17/05	AQ
Aeterna Zentaris : Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 - Form 6-K	16/05	PU
Aeterna Zentaris : Audited Consolidated Financial Statements of Ceapro Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 - Form 6-K	15/05	PU
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	15/05	MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Aeterna Zentaris Reports First Quarter 2024 Financial Results	15/05	AQ
Aeterna Zentaris : MATERIAL CHANGE REPORT - Form 6-K	09/05	PU
Reverse Split: 1 of 4	03/05	FA
Aeterna Zentaris Announces Effective Date of Share Consolidation	01/05	AQ
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

Summary

Filters